In this webinar, we will introduce a new MPS platform designed to address these challenges: the PhysioMimix™ PK – a novel microformulator developed by CN Bio. The original unit was invented by Professor John Wikswo from Vanderbilt University. By delivering dynamic, customized PK profiles for two drugs from human-relevant in vitro biological models, this unique technology provides a means to explore and predict clinically relevant treatment combinations and dosing schedules.
Watch this webinar to learn:
In drug development, microphysiological systems (MPS) are utilized to develop in vitro biological models that can generate more physiologically- and human-relevant data.
However, typical step-changes in drug concentrations from in vitro dosing solutions do not adequately reflect in vivo pharmacokinetic (PK) exposure profiles, potentially resulting in inaccurate ranking of drug effectiveness.